價格 | 詢價 | ||
包裝 | 1支 | 5支 | 10支 |
最小起訂量 | 1支 |
發(fā)貨地 | 北京 |
更新日期 | 2025-04-14 |
中文名稱:VEGFA試劑盒 | 英文名稱:VEGFA ELISA Kit |
品牌: 百普賽斯 | 產(chǎn)地: 北京 |
保存條件: -20°C to -70°C | 純度規(guī)格: 99.9% |
產(chǎn)品類別: ELISA試劑盒 | |
數(shù)量: 999 | 保質(zhì)期: 12個月 |
貨號: EP-137 | 是否進口: 否 |
適應(yīng)物種: Human |
背景(Background)
Kinase insert domain receptor (KDR) is also known as CD309, FLK1, VEGFR, VEGFR2, and is one of the subtypes of VEGFR. VEGF receptors are receptors for vascular endothelial growth factor (VEGF). There are three main subtypes of VEGFR, numbered 1, 2 and 3. The VEGF receptors have an extracellular portion consisting of 7 immunoglobulin-like domains, a single transmembrane spanning region and an intracellular portion containing a split tyrosine-kinase domain. VEGF-A binds to VEGFR-1 (Flt-1) and VEGFR-2 (KDR/Flk-1). VEGFR-2 appears to mediate almost all of the known cellular responses to VEGF.The function of VEGFR-1 is less well defined, although it is thought to modulate VEGFR-2 signaling. Another function of VEGFR-1 may be to act as a dummy/decoy receptor, sequestering VEGF from VEGFR-2 binding (this appears to be particularly important during vasculogenesis in the embryo). In addition, VEGFR2 is able to interact with HIV-1 extracellular Tat protein upon VEGF activation, and seems to enhance angiogenesis in Kaposi's sarcoma lesions.
原理(Assay Principles)
This inhibitor screening ELISA kit is designed to facilitate the identification and characterization of new VEGFA pathway inhibitors. The assay takes advantage of our in house-developed binding of biotinylated human VEGFR2 to immobilized human VEGFA in a functional ELISA assay, and employs a simple colorimetric ELISA platform. Briefly, we provide you with a human Biotinylated VEGFR2 protein, a human VEGFA protein, an anti-VEGFA neutralizing antibody (as method verified Std.), and Streptavidin-HRP reagent.
Your experiment will include 4 simple steps:
a) Coat the plate with human VEGFA.
b) Add your molecule of interest to the tests.
c) Add human VEGFR2-Biotin to bind the coated VEGFA.
d) Add Streptavidin-HRP followed by TMB or other colorimetric HRP substrate.
e) Finally, the half maximal inhibitory concentration (IC50) of your compound to VEGFA: VEGFR2 binding will be determined by comparing OD readings among different experimental groups.
應(yīng)用說明(Application)
This kit is developed for screening for inhibitors of human VEGFA binding to human VEGFR2.
It is for research use only.
重構(gòu)方法(Reconstitution)
Please see Certificate of Analysis for details of reconstitution instruction and specific concentration.
存儲(Storage)
Unopened kit should be stored at 2°C-8°C upon receiving. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
成立日期 | 2010-07-22 (15年) | 注冊資本 | 8000萬人民幣 |
員工人數(shù) | 500人以上 | 年營業(yè)額 | ¥ 1億以上 |
主營行業(yè) | 醫(yī)藥中間體,原料藥,激素類,氨基糖苷類,中樞神經(jīng)系統(tǒng)用藥 | 經(jīng)營模式 | 工廠,試劑 |
產(chǎn)品名稱 | 價格 | 公司名稱 | 報價日期 | |
---|---|---|---|---|
¥1760 |
VIP4年
|
上海博爾森生物科技有限公司
|
2025-04-24 | |
¥2640 |
VIP4年
|
上海博爾森生物科技有限公司
|
2025-04-24 | |
¥2336 |
VIP4年
|
上海博爾森生物科技有限公司
|
2025-04-24 | |
¥2424 |
VIP4年
|
上海博爾森生物科技有限公司
|
2025-04-24 |